Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica has announced that the Therapeutic Products Directorate of Health Canada has accepted for review its new drug submission of oral alitretinoin for the treatment of severe refractory chronic hand eczema.
Subscribe to our email newsletter
Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in several EU member states and in Switzerland.